AVL-292是一个通过共价结合的,可以口头利用,并且具有高度选择性的BTK抑制剂,其IC50小于0.5 nM,展示了比其他被测激酶至少1400倍的选择性。Phase 1.;AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.